GLP-1 receptor agonists represent a transformative advancement in the fight against obesity, a growing global health crisis
In this context, murine studies have shown that sweet taste receptors (TAS1R2 and TAS1R3) are predominantly expressed in the hypothalamus and brainstem, whereas bitter receptors (TAS2R116, TAS2R118, TAS2R138, TAS2R104) are mainly expressed in the arcuate nucleus, ventromedial hypothalamus, dorsomedial hypothalamus, and nucleus of the solitary tract (120, 121)
In terms of appetite suppression onset, many patients report that tirzepatide produces noticeable effects slightly faster, likely due to its dual GIP/GLP-1 mechanism
Liver Int 26(8): 1015-17 Wettergren A et al (1998): Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow